Within Computational Pathology and Biomarkers, we develop AI-powered solutions to advance patient selection, biomarker development, and clinical decision-making at scale. * Drive innovation in AI-powered biomarker development, identifying and applying emerging technologies to BioPharma challenges - At Computational Pathology Munich (CPM), we make a significant contribution to high-performance, data-driven research and development. AstraZeneca's Enterprise AI organization is building the future of drug development by connecting data, technology, and expertise to accelerate breakthroughs across our portfolio. We work collaboratively across the organization to translate innovation into tangible impact across BioPharma, including CVRM, Respiratory & Immunology, and Rare Diseases. to drive the development of AI-enabled computational pathology and multimodal biomarkers that directly ...
mehr